STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 34,296 Shares of Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. acquired 34,296 shares of the company’s stock in a transaction dated Tuesday, March 25th. The shares were purchased at an average price of $17.44 per share, for a total transaction of $598,122.24. Following the purchase, the insider now directly owns 12,319,691 shares of the company’s stock, valued at approximately $214,855,411.04. This trade represents a 0.28 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The stock was purchased at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The shares were acquired at an average cost of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were acquired at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The shares were acquired at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The stock was bought at an average price of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The shares were bought at an average cost of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Trading Down 1.7 %

Shares of NASDAQ STAA opened at $17.46 on Wednesday. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68. The company has a market cap of $861.21 million, a PE ratio of -42.59 and a beta of 0.66. The stock has a 50 day simple moving average of $19.69 and a 200-day simple moving average of $25.43.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Quarry LP bought a new stake in shares of STAAR Surgical during the third quarter valued at about $50,000. Quest Partners LLC acquired a new position in STAAR Surgical during the 3rd quarter valued at about $128,000. KLP Kapitalforvaltning AS bought a new stake in shares of STAAR Surgical during the 4th quarter worth about $180,000. Larson Financial Group LLC lifted its stake in shares of STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after acquiring an additional 2,135 shares during the period. Finally, Bridgefront Capital LLC boosted its holdings in shares of STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock valued at $262,000 after acquiring an additional 2,306 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Jefferies Financial Group cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. BTIG Research downgraded shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Piper Sandler cut their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 12th. Finally, StockNews.com lowered STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.